Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT DEAN ROSEN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1760477335
CMS profile
171185
Location
WINSTON-SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,814.18

208 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,814.18 208

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT DEAN ROSEN

NPI 1760477335 · CMS profile ID 171185

Allopathic & Osteopathic Physicians / Family Medicine

WINSTON-SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760477335?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT DEAN ROSEN, NPI 1760477335, CMS profile ID 171185. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760477335?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBERT DEAN ROSEN, NPI 1760477335, CMS profile ID 171185. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760477335?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBERT DEAN ROSEN, NPI 1760477335, CMS profile ID 171185, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1760477335?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

208 matching records · $3,814.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 208 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 208.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $16.1803/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811380257 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.3703/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763732570 CMS
Lilly USA, LLC $13.7303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818741177 CMS
Merck Sharp & Dohme Corporation $11.1703/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848323569 CMS
Kowa Pharmaceuticals America, Inc. $13.4303/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805566299 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.7103/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763732572 CMS
SANOFI-AVENTIS U.S. LLC $14.2703/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843396427 CMS
Amgen Inc. $12.2703/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825730349 CMS
AbbVie Inc. $15.2003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795880361 CMS
Daiichi Sankyo Inc. $18.2403/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836266559 CMS
Biohaven Pharmaceuticals, Inc. $15.8803/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852604351 CMS
GlaxoSmithKline, LLC. $14.1603/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801585887 CMS
GlaxoSmithKline, LLC. $9.4503/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803046401 CMS
Novartis Pharmaceuticals Corporation $15.5503/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813210863 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.0303/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763732574 CMS
Novo Nordisk Inc $21.7603/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811055933 CMS
AstraZeneca Pharmaceuticals LP $110.5103/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829916707 CMS
Novo Nordisk Inc $16.3003/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811055927 CMS
Eisai Inc. $13.6703/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817861656 CMS
Amgen Inc. $6.2103/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825730353 CMS
PFIZER INC. $12.8403/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833535127 CMS
PFIZER INC. $11.6103/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833447841 CMS
Novo Nordisk Inc $7.2802/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811055919 CMS
Janssen Pharmaceuticals, Inc $14.7802/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788651441 CMS
AbbVie Inc. $10.4502/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795880357 CMS
Biohaven Pharmaceuticals, Inc. $13.1902/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852604347 CMS
GlaxoSmithKline, LLC. $9.0302/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801584213 CMS
Kowa Pharmaceuticals America, Inc. $13.4202/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805566303 CMS
Mylan Specialty L.P. $17.7802/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965402487 CMS
AbbVie Inc. $15.7602/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795880353 CMS
Biohaven Pharmaceuticals, Inc. $19.3602/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852604343 CMS
Ironwood Pharmaceuticals, Inc $13.8102/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855129825 CMS
AbbVie Inc. $13.4402/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795880349 CMS
Xeris Pharmaceuticals, Inc. $14.5602/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837442981 CMS
AstraZeneca Pharmaceuticals LP $61.1202/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829896241 CMS
Merck Sharp & Dohme Corporation $15.7502/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848561183 CMS
AbbVie Inc. $5.7202/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795880345 CMS
Lilly USA, LLC $14.4502/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818735627 CMS
Astellas Pharma US Inc $13.8802/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821520479 CMS
Lilly USA, LLC $13.9102/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818714199 CMS
AbbVie Inc. $11.0602/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795880341 CMS
SANOFI-AVENTIS U.S. LLC $16.5501/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843396403 CMS
AbbVie Inc. $10.8201/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795880337 CMS
AstraZeneca Pharmaceuticals LP $13.3601/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829780697 CMS
Janssen Pharmaceuticals, Inc $11.4501/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788651445 CMS
AbbVie Inc. $11.0901/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795880333 CMS
GlaxoSmithKline, LLC. $9.3701/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802153747 CMS
Novo Nordisk Inc $12.7401/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810852289 CMS
AstraZeneca Pharmaceuticals LP $12.8401/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829693807 CMS
PFIZER INC. $9.4201/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832606957 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,470.51 177
PY2020 $2,402.66 162
PY2021 $3,814.18 208
PY2022 $3,262.24 179
PY2023 $3,543.91 147
PY2024 $4,759.56 120
PY2025 $9,129.73 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $197,565.43 61
PY2024 Principal investigator $124,468.63 8
PY2023 Principal investigator $695,763.01 87
PY2022 Principal investigator $643,457.54 50
PY2021 Principal investigator $152,673.10 65
PY2020 Principal investigator $53,844.60 48
PY2019 Principal investigator $44,590.38 42

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seqirus USA Inc $472.50 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287754
Principal investigator 1 Seqirus USA Inc $472.50 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287756
Principal investigator 1 Seqirus USA Inc $472.50 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287766
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287848
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287850
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287852
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287854
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287856
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287858
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287860
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287862
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287864
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287866
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287868
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287870
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287872
Principal investigator 1 Seqirus USA Inc $1,352.40 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287952
Principal investigator 1 Seqirus USA Inc $1,352.40 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287954
Principal investigator 1 Seqirus USA Inc $1,352.40 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287956
Principal investigator 1 Seqirus USA Inc $1,352.40 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287958
Principal investigator 1 Seqirus USA Inc $1,352.40 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287960
Principal investigator 1 Seqirus USA Inc $472.50 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287970
Principal investigator 1 Seqirus USA Inc $1,352.40 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287977
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287980
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287982
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287984
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287986
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287990
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287992
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287994
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287996
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185287998
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288000
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288002
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288004
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288006
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288008
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288010
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288012
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288014
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288016
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288018
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288020
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288033
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288036
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288038
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288040
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288042
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288044
Principal investigator 1 Seqirus USA Inc $4,062.10 12/19/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288046
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,559.70 11/25/2025 Non-covered Recipient Entity
Clinica Humanitaria Maywood
BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. No dispute reported 06/30/2026 1225419837
Principal investigator 1 Seqirus USA Inc $2,564.40 11/04/2025 Non-covered Recipient Entity
Progressive Medicine of the Triad, LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810931
Principal investigator 1 Seqirus USA Inc $704.70 11/04/2025 Non-covered Recipient Entity
Progressive Medicine of the Triad, LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810935
Principal investigator 1 Seqirus USA Inc $3,000.00 10/06/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290290
Principal investigator 1 Seqirus USA Inc $13,500.00 10/06/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290306
Principal investigator 1 Seqirus USA Inc $418.81 09/09/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290248
Principal investigator 1 Seqirus USA Inc $110.98 09/03/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290220
Principal investigator 1 Seqirus USA Inc $946.80 09/03/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290266
Principal investigator 1 Seqirus USA Inc $111.30 09/03/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290412
Principal investigator 1 Seqirus USA Inc $360.34 08/15/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290244
Principal investigator 1 Visby Medical, Inc. $800.00 05/15/2025 Non-covered Recipient Entity
Progressive Medicine of the Triad, LLC
A Prospective Study to Collect Samples for Reserach and Development of Visby Medical Products Relating to Respiratory Infections No dispute reported 06/30/2026 1207799115